Almirall (Almirall) ROCE % : 9.51% (As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Almirall ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Almirall's annualized ROCE % for the quarter that ended in Jun. 2023 was 9.51%.

Almirall ROCE % Historical Data

The historical data trend for Almirall's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Almirall ROCE % Chart

Almirall Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

6.22

4.81

0.20

1.89

-0.52

Almirall Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															9.84	-	-2.40	9.51	-

Almirall ROCE % Calculation

Almirall's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-10.887	/	( ( (2275.096 - 290.904)	+	(2589.951 - 382.852) )	/ 2 )
	=	-10.887	/	( (1984.192	+	2207.099)	/ 2 )
	=	-10.887	/	2095.6455
	=	-0.52 %

Almirall's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	202.432	/	( ( (2274.09 - 258.03)	+	(2535.044 - 294.603) )	/ 2 )
	=	202.432	/	( ( 2016.06	+	2240.441 )	/ 2 )
	=	202.432	/	2128.2505
	=	9.51 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

Almirall (OTCPK:LBTSF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Almirall ROCE % Related Terms

Thank you for viewing the detailed overview of Almirall's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Almirall (Almirall) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Almirall SA (OTCPK:LBTSF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

0O9B:UK ALM:Spain E2Z:Germany

Address

Ronda General Mitre 151, Barcelona, ESP, 08022

Website

http://www.almirall.es

Almirall SA is a Spain-based company engaged in development, manufacture, and selling pharmaceutical products across a range of therapeutic areas. It aims to provide treatments in areas of dermatology, respiratory, gastrointestinal, central nervous systems, and other specialties. The company operates in five segments: Sales of its own network, sales of licensees, Research and developments, Sales of Therapeutic dermatological products in the U.S., and Corporate management. The medical dermatology business in the Europe is the key driver of the company's operation. Other than Europe, the company also operates in the Americas, Asia, Africa, and Oceania through subsidiaries.